Sep 2026· Cancer Medicine· Vol 15· 1 citation· 25 references
Medicine
TL;DR
It is concluded that ctDNA is a potential predictor of inferior survival outcomes in MM patients.
Abstract
Circulating tumor DNA (ctDNA) serves as a non‐invasive liquid biopsy technique, offering potential utility in the prognostic evaluation of multiple myeloma (MM). In this study, we performed a systematic review and updated meta‐analysis to analyze the association between ctDNA and the prognosis of patients diagnosed with MM. A comprehensive literature search was performed across PubMed, Embase, Web of Science, and the Cochrane Library to retrieve relevant literature published up to May 29, 2025, assessing the impact of ctDNA on survival outcomes in patients with MM. The survival outcomes included overall survival (OS), progression‐free survival (PFS), and time to progression (TTP). A total of 948 MM patients from 14 studies were included in the analysis. Patients with detectable ctDNA exhibited a significantly increased risk of aggressive disease progression (hazard ratio [HR], 3.21; 95% confidence interval [CI], 1.98–5.18) and reduced OS (HR, 3.97; 95% CI, 2.24–7.04). Subgroup analyses consistently indicated that ctDNA positivity was associated with accelerated disease progression, irrespective of race, disease status, treatment, or ctDNA detection method. In subgroups defined by relapsed or refractory MM (RRMM) and Oceanian or Caucasian race, ctDNA positivity was significantly correlated with poorer OS. However, the associations were not significant in newly diagnosed MM (NDMM) or among Asian patients. Therefore, we conclude that ctDNA is a potential predictor of inferior survival outcomes in MM patients.
The meta-analysis revealed a significant correlation between positive ctDNA status and worse survival outcomes, including DFS/RFS, and ctDNA consistently predicted worse survival outcomes for patients with rectal cancer.
Tao Jin, Er-Shuo Du, Xiao-Rui Fu et al.· BMC Cancer· 0 citations
Despite curative-intent surgery, recurrence remains a major cause of mortality in gastric cancer, while conventional clinicopathological staging provides limited accuracy for postoperative risk stratification. Circulating tumor DNA (ctDNA), a promising biomarker of molecular residual disease (MRD), has emerged as...
Yu-Fang Kong, Ling Yuan, Rong Kuang et al.· World Journal of Surgical On...· 0 citations
BACKGROUND
The prognostic value of circulating tumor DNA (ctDNA) remains controversial. This meta-analysis systematically evaluates the association between ctDNA status and prognosis in esophageal cancer (EC) and gastric cancer (GC) (including gastroesophageal junction cancer), stratified by resectability and treatment...
Shao-Qing Ding, Min-Yuan Ni, Ze-Qi Tang et al.· Critical reviews in oncology...· 0 citations
An association between baseline ctDNA levels, on-treatment changes in ctDNA levels, and survival outcomes in ABC is supported and specific genetic alterations in ctDNA add prognostic information and may support treatment tailoring.
Cæcilie Ottosen, E. Kragelund, M. A. Pedersen et al.· Breast Cancer Research and T...· 0 citations
BACKGROUND AND AIMS
Interleukin-6 (IL-6) has been implicated in the pathogenesis of hepatocellular carcinoma (HCC) and resistance to systemic therapy. This study aimed to evaluate the prognostic value of circulating IL-6 in patients with HCC receiving systemic therapy through a systematic review and meta-analysis.
ME...
Y. Perfilyeva, N. Abdolla, A. Kali et al.· Future Oncology· 0 citations
Circulating tumor DNA (ctDNA) is an emerging biomarker in hematologic malignancies, and elevated ctDNA levels may reflect higher tumor burden. Its prognostic significance in patients undergoing chimeric antigen receptor T-cell (CAR-T) therapy or immune checkpoint inhibitors (ICIs) remains debatable. The purpose of...
Cong-Cong Wang, Zhi-Bing Jiang, Jiao-Jiao Qiao et al.· Frontiers in Immunology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.